Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
CNBC Stocks· Oct 29, 2026 · 11:24 AM
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 1 hour ago
Tech risk-reward turns favorable after rout, Deutsche Bank says
Investing.com
stocksabout 1 hour ago
Power bills and data centers cast rare spotlight on utilities in US midterms
Investing.com
stocksabout 1 hour ago
Anthropic's path to the Nasdaq just got a lot bumpier
Concerning projections from hyperscalers this week punished tech stocks and pushed the Nasdaq to its first three-week losing streak since March.
CNBC Stocks